戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 n with and without ovarian cancer (none with hematologic disorder).
2 le cell disease (SCD) is a common hereditary hematologic disorder.
3  >=1 hypomethylating agent for an antecedent hematologic disorder.
4 hest used to date to investigate a malignant hematologic disorder.
5     Polycythemia vera (PV) is a human clonal hematologic disorder.
6 at tune hematopoiesis at steady state and in hematologic disorders.
7  underpinnings of nonmalignant and malignant hematologic disorders.
8 oaches to correct defective hematopoiesis in hematologic disorders.
9 ms were significantly associated with NPC or hematologic disorders.
10 evaluating novel gene editing strategies for hematologic disorders.
11 ogous HCT exposure; and patients with benign hematologic disorders.
12  treatment of patients with life-threatening hematologic disorders.
13  improvements in the management of inherited hematologic disorders.
14 od of some persons who are not known to have hematologic disorders.
15 c stem and progenitor cells and treatment of hematologic disorders.
16  more frequently in the treatment of various hematologic disorders.
17 n myelodysplastic syndromes (MDSs) and other hematologic disorders.
18 g as new therapeutics for cardiovascular and hematologic disorders.
19 stem cell gene transfer for the treatment of hematologic disorders.
20 etic stem cells transplantation for treating hematologic disorders.
21 ble diagnostic and prognostic information in hematologic disorders.
22 -saving treatment modality for patients with hematologic disorders.
23 eserve and renewal capacity in patients with hematologic disorders.
24 isense approach targeting Bcl-2 in malignant hematologic disorders.
25 keletal muscle of animal models of inherited hematologic disorders.
26 lar bases of numerous acquired and inherited hematologic disorders.
27 lts in cardiovascular, renal, placental, and hematologic disorders.
28 sible for patients with a growing variety of hematologic disorders.
29 ll proliferation that may be associated with hematologic disorders.
30 rapy holds promise for the treatment of many hematologic disorders.
31 er studies of HITT and other immune-mediated hematologic disorders.
32 is disease to transform into more aggressive hematologic disorders.
33 apies for patients with benign and malignant hematologic disorders.
34 reatment for both malignant and nonmalignant hematologic disorders.
35 in care and therapeutics as those with other hematologic disorders.
36 valent in elderly individuals who lack overt hematologic disorders.
37 0); systemic mastocytosis with an associated hematologic disorder, 1320 (n = 7); aggressive mastocyto
38 ommon causes included vasculitis (34.6%) and hematologic disorders (27.4%).
39 OG) performance status 2; 51% for antecedent hematologic disorder; 54% for intermediate karyotype; 42
40 tic, neurodevelopmental, cardiovascular, and hematologic disorders (8% each); and others.
41 e thrombocytopenic purpura (ITP) is a common hematologic disorder; about 14,000 to 16,000 new cases o
42                                              Hematologic disorders account for a large proportion of
43 development of new therapies for the primary hematologic disorder and organ system manifestations.
44 peutic option for patients with nonmalignant hematologic disorders and can mediate immune tolerance t
45 ophil number and survival are common to both hematologic disorders and chronic inflammatory diseases.
46  with high rates of success for a variety of hematologic disorders and metabolic storage diseases in
47  44) compared with the sera of patients with hematologic disorders and no histologic evidence of fibr
48 erse effects and benefits of splenectomy for hematologic disorders and other conditions demand furthe
49 infectious, gastrointestinal, metabolic, and hematologic disorders and their treatments; length of ho
50 ormance status, or presence of an antecedent hematologic disorder, and multivariate analysis indicate
51 cystitis, pancreatitis, choledocholithiasis, hematologic disorders, and emergent procedures.
52 t, treatment recommendations for less common hematologic disorders are consistent with current standa
53                                          The hematologic disorders are described, and a correlation w
54 agnosing, treating, and palliating malignant hematologic disorders are inadequate.
55 ), but not blood cells from normals or other hematologic disorders, are resistant to the cytotoxic ef
56 file of Mood States (POMS) for patients with hematologic disorders as compared with patients with bre
57 anding indications for HCT to include benign hematologic disorders as well as autoimmune diseases man
58 , local or systemic infections, vascular and hematologic disorders, autoimmune diseases, and environm
59 e to rule out BM involvement in a variety of hematologic disorders before or after therapy.
60 c cell transplantation (HCT) is curative for hematologic disorders, but outcomes are historically inf
61  of gene therapy strategies for treatment of hematologic disorders by AdVec.
62               Sickle cell disease (SCD) is a hematologic disorder caused by a missense mutation in th
63 sease (iMCD) is a rare and poorly understood hematologic disorder characterized by lymphadenopathy, s
64             Castleman disease (CD) is a rare hematologic disorder characterized by pathologic lymph n
65 opathic hypereosinophilic syndrome is a rare hematologic disorder characterized by sustained unexplai
66 phohistiocytosis (HLH) is a life-threatening hematologic disorder characterized by unchecked immune a
67 oplasms (MPNs) are a group of related clonal hematologic disorders characterized by excess accumulati
68 romes (MDS) comprise a group of premalignant hematologic disorders characterized by ineffective hemat
69   Myelodysplastic syndromes (MDS) are clonal hematologic disorders characterized by morphologic abnor
70               The diagnosis and treatment of hematologic disorders depend on the integration of diver
71 zation mutations are largely associated with hematologic disorders, display dimerization haploinsuffi
72  consequence, many human leukemias and other hematologic disorders do not robustly engraft in these c
73  wide spectrum of nonmalignant and malignant hematologic disorders, genetic disorders, and solid tumo
74 us-host disease, viral infections, malignant hematologic disorders, hemophilia, and the hemoglobin di
75 l types of malignant hematologic disease and hematologic disorders; however, these patients have an i
76                                          The hematologic disorder in these patients is more consisten
77     NS is also associated with a spectrum of hematologic disorders, including juvenile myelomonocytic
78 een associated with BM fibrosis in disparate hematologic disorders, including MPN and gray platelet s
79 enesis has been demonstrated in a variety of hematologic disorders, including multiple myeloma.
80  sequencing that have been applied to benign hematologic disorders, including those affecting the red
81  granulomatous disease (CGD) is an inherited hematologic disorder involving failure of phagocytic cel
82  purpura (ITP) is the most common autoimmune hematologic disorder, little is known about the associat
83 c thrombocytopenic purpura (ITP) is a common hematologic disorder manifested by immune-mediated throm
84 emonstrates high prevalence in patients with hematologic disorders, most commonly sickle cell disease
85                                       No new hematologic disorders occurred.
86                                   Neoplastic hematologic disorders of the myeloid lineage have been r
87 e any AML disease arising from an antecedent hematologic disorder or after prior cytotoxic or radiati
88 netic subgroup, age, and history of previous hematologic disorder or antineoplastic therapy.
89  years); 22 patients (59%) had an antecedent hematologic disorder or myelodysplastic syndrome or both
90 tients), leukemia arising from an antecedent hematologic disorder or prior cytotoxic therapy (seconda
91                Nineteen (36%) had antecedent hematologic disorder or therapy-related AML; 16 had comp
92 , but not in marrow from patients with other hematologic disorders or controls, and support an import
93  years), we estimated the cumulative risk of hematologic disorders originating from lymphoid and myel
94 rable cytogenetics (P < .001) and antecedent hematologic disorder (P < .001), and had a higher presen
95 ere negatively correlated with an antecedent hematologic disorder (P = .002) but not with age or cyto
96 and ischemic heart disease), coagulation and hematologic disorders (pulmonary embolism and deep vein
97     Sixty-eight adults with life-threatening hematologic disorders received intensive chemotherapy or
98 for the pathogenesis of these poor prognosis hematologic disorders remain controversial.
99 ic disorders (SR, 1.19 [95% CI, 1.00-1.40]), hematologic disorders (SR, 1.26 [95% CI, 1.06-1.47]), mu
100                                              Hematologic disorders such as aplastic anemia and leukem
101                          The pathogenesis of hematologic disorders such as aplastic anemia and the de
102 clinical and preclinical settings, including hematologic disorders such as the hemophilias, Gaucher d
103 lications for the earliest events that drive hematologic disorders, suggesting that chronic inflammat
104      For the psychologic data, patients with hematologic disorders tended to be more distressed than
105 e treatment of multiple myeloma, a malignant hematologic disorder that can produce significant amount
106 e myelodysplastic syndrome (MDS) is a clonal hematologic disorder that frequently evolves to acute my
107   Myelodysplastic syndromes (MDS) are common hematologic disorders that are characterized by decrease
108  Myelodysplastic syndromes (MDSs) are clonal hematologic disorders that frequently represent an inter
109 The myelodysplastic syndromes are a group of hematologic disorders that often evolve into secondary a
110 ditioning is a cure for several nonmalignant hematologic disorders that require chronic transfusion,
111 alpha might be involved in several malignant hematologic disorders, the mutational status of this reg
112  a curative therapy for several nonmalignant hematologic disorders through the provision of donor-der
113 light chain (AL) amyloidosis is an incurable hematologic disorder typically characterized by the prod
114 greater than 50 IU/L (P = .02), diagnosis of hematologic disorder versus solid tumor (P = .06), serum
115 ction mutation of Cxcr4 described in 2 human hematologic disorders, warts, hypogammaglobulinemia, inf
116                                An underlying hematologic disorder was detected in 69 patients (78%).
117                                 A search for hematologic disorders was negative.
118                                              Hematologic disorders were associated with the highest h
119 tients with ongoing renal failure or chronic hematologic disorders were excluded.
120                                              Hematologic disorders were present in 66% of patients, i
121 ologic measures when comparing patients with hematologic disorders with those with breast cancer.
122  growing majority of patients diagnosed with hematologic disorders, yet they remain underrepresented

 
Page Top